Related Experiment Video
Updated: Jun 17, 2026

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
Full-length hepatitis B virus sequences from naïve patients with fluctuation of viral load during ADV monotherapy
Yongwei Li1, Mingfen Zhu, Yunwei Guo
1Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Abstract:
The reasons for adefovir dipivoxil (ADV) treatment failures appear diverse. Few studies have reported full-length hepatitis B virus (HBV) genome in patients with ADV treatment failures. The patients were from a phase III clinical trial that investigated the antiviral response to ADV in China. Seven patients had increase in HBV-DNA (>1 log(10) copies/ml above on-treatment nadir) at week 52. The serum HBV-DNA levels were above 10(4)copies/ml at week 92 in four of them. Sixteen full-length HBV genomes from the four patients at four time points were sequenced using cloning sequencing method. The frequency of substitutions at week 52 was higher than at weeks 28(16 wt) and 92(80). HBV-DNA reduction was correlated negatively with the frequency of substitutions at the three time points. No published ADV-resistant mutations were detected. The mutations, including substitutions in immunogenic epitopes and conserved sites of the polymerase gene, were frequent during ADV treatment. Amino acid deletions in X gene and basal core promoter/pre-core mutations appeared before or during ADV treatment. The substitutions in immunogenic epitopes (mainly of the surface gene) and conserved sites of the polymerase gene other than ADV-resistant mutations may have influenced antiviral efficacy in the study. More potent antiviral drugs may be important to rescue individual patients and for public health safety. It is needed to study how these substitutions influence HBV replication, disease progression, and antiviral treatment efficacy.
Insights
Adefovir dipivoxil (ADV) treatment failures in hepatitis B virus (HBV) patients were linked to frequent viral mutations, not previously identified ADV-resistant ones. These genetic changes may impact treatment effectiveness and disease progression.
Area of Science:
- Hepatology
- Virology
- Genetics
Background:
- Adefovir dipivoxil (ADV) is used to treat chronic hepatitis B virus (HBV) infection.
- Treatment failures with ADV can occur, but the underlying viral genetic factors are not fully understood.
- Previous studies have limited data on full-length HBV genomes from patients experiencing ADV treatment failure.
Purpose of the Study:
- To investigate the full-length hepatitis B virus (HBV) genome in patients experiencing adefovir dipivoxil (ADV) treatment failure.
- To identify viral mutations associated with ADV treatment failure.
- To explore the potential impact of these mutations on antiviral efficacy.
Main Methods:
- Sequencing of 16 full-length HBV genomes from four patients who experienced treatment failure during a phase III clinical trial.
- Analysis of viral substitutions at multiple time points (weeks 28, 52, and 92).
- Correlation analysis between HBV-DNA levels, viral substitution frequency, and treatment outcomes.
Main Results:
- No known adefovir dipivoxil-resistant mutations were detected in the studied patients.
- A higher frequency of viral substitutions was observed at week 52, correlating negatively with HBV-DNA reduction.
- Mutations in immunogenic epitopes and conserved polymerase gene sites, along with deletions in the X gene and basal core promoter/pre-core mutations, were noted during ADV treatment.
Conclusions:
- Viral genetic changes, including mutations in epitopes and conserved regions, may contribute to adefovir dipivoxil treatment failure, independent of known resistance mutations.
- Further research is needed to understand how these specific substitutions influence HBV replication, disease progression, and treatment response.
- The development of more potent antiviral agents may be crucial for managing ADV treatment failures and ensuring public health.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Viruses with RNA Genomes
Inhibitors of Viral Protein Synthesis
